Check-Cap ( (CHEK) ) has shared an update.
Check-Cap Ltd. recently received a notification from Nasdaq on April 9, 2025, indicating non-compliance with the minimum bid price requirement, as the company’s shares fell below $1 for 30 consecutive business days. The company has until October 6, 2025, to regain compliance, with the possibility of an additional 180-day extension if certain conditions are met. Additionally, Check-Cap appointed Alan Lewis as the new Chief Financial Officer and RBSM LLP as its new independent registered public accounting firm on April 6, 2025, signaling strategic changes in its financial management and auditing practices.
Spark’s Take on CHEK Stock
According to Spark, TipRanks’ AI Analyst, CHEK is a Underperform.
Check-Cap’s overall score reflects its significant financial challenges, primarily due to a lack of revenue generation and persistent losses. While the technical analysis hints at possible recovery, the valuation is weak due to negative profitability indicators. The company’s strong equity position is a positive aspect, but without revenue, it faces substantial risks.
To see Spark’s full report on CHEK stock, click here.
More about Check-Cap
Check-Cap Ltd. operates in the medical technology industry, focusing on the development of innovative diagnostic products. The company is known for its capsule-based screening technology designed to detect colorectal cancer, aiming to provide a patient-friendly alternative to traditional colonoscopy procedures.
YTD Price Performance: -43.71%
Average Trading Volume: 172,345
Technical Sentiment Signal: Buy
Current Market Cap: $3.82M
For an in-depth examination of CHEK stock, go to TipRanks’ Stock Analysis page.